2.17 USD
-0.22 (-9.21%)
Overall CPIX gets a fundamental rating of 3 out of 10. We evaluated CPIX against 191 industry peers in the Pharmaceuticals industry. CPIX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CPIX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
CPIX had positive earnings in the past year.
In the past year CPIX had a positive cash flow from operations.
CPIX had negative earnings in each of the past 5 years.
Of the past 5 years CPIX 4 years had a positive operating cash flow.
1.2 Ratios
CPIX has a better Return On Assets (-5.05%) than 71.73% of its industry peers.
The Return On Equity of CPIX (-12.74%) is better than 70.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.05% | ||
| ROE | -12.74% | ||
| ROIC | N/A |
ROA(3y)-7.42%
ROA(5y)-5.97%
ROE(3y)-21.64%
ROE(5y)-16.04%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CPIX has a better Gross Margin (84.49%) than 87.43% of its industry peers.
CPIX's Gross Margin has been stable in the last couple of years.
CPIX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.04%
2. Health
2.1 Basic Checks
CPIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CPIX has less shares outstanding than it did 1 year ago.
CPIX has less shares outstanding than it did 5 years ago.
The debt/assets ratio for CPIX is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.52, we must say that CPIX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.52, CPIX perfoms like the industry average, outperforming 50.26% of the companies in the same industry.
CPIX has a debt to FCF ratio of 0.79. This is a very positive value and a sign of high solvency as it would only need 0.79 years to pay back of all of its debts.
CPIX has a better Debt to FCF ratio (0.79) than 96.34% of its industry peers.
CPIX has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
CPIX's Debt to Equity ratio of 0.20 is in line compared to the rest of the industry. CPIX outperforms 45.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 0.79 | ||
| Altman-Z | 0.52 |
ROIC/WACCN/A
WACC8.59%
2.3 Liquidity
CPIX has a Current Ratio of 1.23. This is a normal value and indicates that CPIX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.23, CPIX is doing worse than 79.06% of the companies in the same industry.
CPIX has a Quick Ratio of 1.11. This is a normal value and indicates that CPIX is financially healthy and should not expect problems in meeting its short term obligations.
CPIX has a Quick ratio of 1.11. This is in the lower half of the industry: CPIX underperforms 75.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.11 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 158.82% over the past year.
Looking at the last year, CPIX shows a quite strong growth in Revenue. The Revenue has grown by 12.21% in the last year.
Measured over the past years, CPIX shows a small growth in Revenue. The Revenue has been growing by 1.95% on average per year.
EPS 1Y (TTM)158.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)12.21%
Revenue growth 3Y1.71%
Revenue growth 5Y1.95%
Sales Q2Q%-8.8%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 21.70, the valuation of CPIX can be described as rather expensive.
CPIX's Price/Earnings ratio is a bit cheaper when compared to the industry. CPIX is cheaper than 79.58% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.34, CPIX is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.7 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CPIX indicates a somewhat cheap valuation: CPIX is cheaper than 76.44% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CPIX indicates a rather cheap valuation: CPIX is cheaper than 96.86% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.87 | ||
| EV/EBITDA | 46.75 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CPIX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CPIX (12/8/2025, 8:01:27 PM)
2.17
-0.22 (-9.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners22.93%
Inst Owner Change-7.47%
Ins Owners3.51%
Ins Owner Change0.02%
Market Cap32.46M
Revenue(TTM)41.28M
Net Income(TTM)-3.33M
Analysts43.33
Price TargetN/A
Short Float %0.39%
Short Ratio0.69
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.7 | ||
| Fwd PE | N/A | ||
| P/S | 0.79 | ||
| P/FCF | 4.87 | ||
| P/OCF | 4.75 | ||
| P/B | 1.24 | ||
| P/tB | 3.18 | ||
| EV/EBITDA | 46.75 |
EPS(TTM)0.1
EY4.61%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.45
FCFY20.54%
OCF(TTM)0.46
OCFY21.05%
SpS2.76
BVpS1.75
TBVpS0.68
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.98
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.05% | ||
| ROE | -12.74% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.49% | ||
| FCFM | 16.16% |
ROA(3y)-7.42%
ROA(5y)-5.97%
ROE(3y)-21.64%
ROE(5y)-16.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.04%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 0.79 | ||
| Debt/EBITDA | 10.89 | ||
| Cap/Depr | 4.41% | ||
| Cap/Sales | 0.4% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 1419.63% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.11 | ||
| Altman-Z | 0.52 |
F-Score8
WACC8.59%
ROIC/WACCN/A
Cap/Depr(3y)17.26%
Cap/Depr(5y)20.78%
Cap/Sales(3y)2.19%
Cap/Sales(5y)2.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.21%
Revenue growth 3Y1.71%
Revenue growth 5Y1.95%
Sales Q2Q%-8.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.37%
OCF growth 3YN/A
OCF growth 5YN/A
CUMBERLAND PHARMACEUTICALS / CPIX FAQ
Can you provide the ChartMill fundamental rating for CUMBERLAND PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 3 / 10 to CPIX.
What is the valuation status of CUMBERLAND PHARMACEUTICALS (CPIX) stock?
ChartMill assigns a valuation rating of 3 / 10 to CUMBERLAND PHARMACEUTICALS (CPIX). This can be considered as Overvalued.
Can you provide the profitability details for CUMBERLAND PHARMACEUTICALS?
CUMBERLAND PHARMACEUTICALS (CPIX) has a profitability rating of 3 / 10.